GLP1R and metabolic dysfunction-associated steatotic liver disease: GLP-1 receptor agonists (GLP-1RA), a new hypoglycemic drug, has been increasingly proved its efficacy and safety in individuals with NAFLD, which can not only reduce hepatic steatosis and inflammation, but improve non-alcoholic steatohepatitis (NASH) (47).